Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
SHARE THIS ARTICLE
PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics, will join top biopharmaceutical leaders for two-days of discussion on January 11 – 12, 2025 hosted by Longwood Healthcare Leaders. The meeting gathers leaders from government, pharma, biotech, academia, and investment communities to address critical challenges facing the life sciences ecosystem today.
Additionally, Mr. Pham is honored to join leading healthcare executives at the prestigious Nasdaq Opening Bell Ceremony on Monday, January 13, 2025, in conjunction with the first day of the 43rd Annual J.P. Morgan Healthcare Conference. Taking place from 5:30 AM to 7:30 AM PT at the Nasdaq Entrepreneurial Center in San Francisco, the event will set the stage for a dynamic week of activities that will shape the healthcare and life sciences sector in 2025.
Mr. Pham and Chief Operating Officer, Jeff Cole, will join one-on-one investor and partnering meetings during the 43rd J.P. Morgan Healthcare Conference Week to provide updates on the development of tecarfarin and its potential to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. This update will outline the company’s roadmap for finalization of the clinical development plan for regulatory approval and pre-commercial activities for tecarfarin and key business and strategic priorities for 2025. To schedule a meeting with management, please contact Patrick Mikus at LaVoieHealthScience at (617) 351-0244 or pmikus@lavoieheatlhscience.com.
“We look forward to take part in these key events around the 43rd Annual J.P. Morgan Healthcare Conference Week, as they provide an invaluable platform to share our 2025 Phase 3 clinical development and regulatory execution plan for tecarfarin and our three-year vision for Cadrenal,” said Mr. Pham.
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc.is a biopharmaceutical company in advanced clinical development focused on tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.
Tecarfarin is a vitamin K antagonist (VKA) representing the first new innovation in 70 years in VKA anticoagulation. Tecarfarin is designed to be a superior and safer chronic anticoagulant oral therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal Therapeutics’ Phase 3-ready drug candidate, tecarfarin, is supported by extensive data demonstrating its potential as an alternative to warfarin, resulting in fewer adverse events such as strokes, heart attacks, bleeds, and deaths. Tecarfarin received an orphan drug designation for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. The company also plans to investigate tecarfarin in patients with mechanical heart valves who face anticoagulation challenges due to genetic warfarin resistance, polypharmacy, or kidney impairment.
For more information, please visit www.cadrenal.com . and connect with the company on LinkedIn.
Safe Harbor
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include statements regarding tecarfarin’s potential to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to be a more effective anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241218991058/en/
Corporate and Investor Relations
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
MASTER LEGAL DISCLAIMER
Effective Date: August 2024
Last Updated: May 17, 2025
Publisher: Relqo Media LLC (Wyoming, United States)
Subject Company: Cadrenal Therapeutics, Inc. (CVKD)
IMPORTANT SUMMARY — PLEASE READ FIRST
This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Genesis One Holdings LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.
1. NATURE AND INTENT OF THIS COMMUNICATION
Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.
2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)
Relqo Media LLC has been retained by Genesis One Holdings LLC to provide promotional media services for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). As of the effective date:
- Relqo Media LLC is receiving cash compensation for digital investor awareness campaigns.
- The total compensation paid for these services is $25,000 per week, paid weekly, for the period beginning January 1, 2025 through July 1, 2025, totaling $650,000.
- Genesis One Holdings LLC may own, acquire, or dispose of shares in CVKD during or after the campaign period.
This relationship creates a material conflict of interest. Relqo Media’s content regarding CVKD should be considered promotional, biased, and financially motivated.
3. INTENDED AUDIENCE
These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.
4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS
Relqo Media LLC does not independently verify, investigate, or audit any statements made by the company being promoted, its officers, its press releases, or any third-party sources. Any claims, projections, customer announcements, or product statements made in connection with CVKD should be assumed to be unverified and potentially inaccurate unless independently confirmed. You should not rely on any statements regarding future performance, partnerships, revenue projections, or corporate plans.
5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION
Promotional campaigns commonly result in short-lived spikes in stock price and volume, followed by rapid declines. These spikes are typically driven by retail speculation, promotional circulation, and momentary investor interest—not fundamentals. You should expect that:
- CVKD’s stock may increase temporarily during this promotion,
- Trading volume may rise sharply, and
- The price may fall after the campaign ends or selling begins.
These patterns are typical of stock promotions, and you should proceed accordingly.
6. NO RELIANCE – INVESTOR RESPONSIBILITY
The burden of research, investigation, and risk assessment rests solely with you. Relqo Media LLC is not responsible for your investment decisions. You are strongly urged to:
- Read public filings from the SEC,
- Consult a licensed financial adviser,
- Understand risks such as dilution, insider selling, and volatility, and
- Recognize that speculative stocks often lack financial transparency.
We accept no responsibility for losses incurred due to actions taken based on our Communications.
7. FORWARD-LOOKING STATEMENTS AND SAFE HARBOR
Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about potential growth, revenue forecasts, market opportunity, strategic partnerships, or technological development. Such statements are speculative and based on assumptions that may never occur. Actual results may differ materially. These statements are made under the safe harbor protections of Sections 27A and 21E of the Securities Acts. Relqo Media disclaims any duty to update them.
8. INFORMATION SOURCING, BIAS, AND ACCURACY
We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.
Assume all information presented by Relqo Media is:
- Subjective,
- Not independently verified,
- Created to highlight potential upside and omit downsides,
- Not suitable as the basis for any investment decision.
9. OWNERSHIP AND TRADING CONFLICTS
Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.
10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT
We use a range of outreach and promotional tools, including:
- Email and newsletter distributions,
- SMS/MMS text campaigns,
- Social media posts and influencers,
- Google and native display ads,
- Press releases, video marketing, and paid content distribution.
By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.
11. ADVERTISING LAW COMPLIANCE
Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.
We make good-faith efforts to disclose all:
- Compensation arrangements,
- Conflicts of interest,
- Risks,
- Limitations of our role, and
- The promotional nature of this content.
We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.
12. NON-U.S. USERS
This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.
13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY
All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:
- Investment losses,
- Inaccuracies,
- Technical delays,
- User misunderstandings,
- Omissions or errors in content.
Total liability for any claim shall not exceed one hundred dollars ($100).
14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION
All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.
15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS
Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.
16. FINAL NOTICE – ACCEPTANCE OF TERMS
We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.
If you do not accept all terms of this disclaimer in full, you must:
- Exit our websites,
- Unsubscribe from our communications,
- Discontinue viewing all Relqo Media promotional content.
17. NO RELIANCE
By viewing or engaging with this content, you agree that:
- You will not rely on any statements made by Relqo Media for investment purposes,
- You waive any claim that our content was a material factor in your investment decision,
- You have read, understood, and accepted this disclaimer in full.
© 2024 Relqo Media LLC. All Rights Reserved.
Legal Contact: 📧 support@stockverse.com
Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801
Affiliate Disclosure: Relqo Media LLC owns and operates Stockverse.com and all affiliated digital properties.